Back to Market返回行情

CVRX CVRx, Inc.

USHealthcare
$5.43+4.42%ClosedMarket Cap: $144.1M

As of 2026-07-10 16:00

Why CVRX matters now

CVRx, Inc. (CVRX) is a US stock in Healthcare. The latest InvestLog snapshot shows $5.43 with +4.42% on the session and $144.1M in market capitalization; recent performance reads 1-month -17.64% and YTD -30.28%.

The latest financial table shown here is Q1 2026, with revenue of $14.8M, net income of $-13.1M, and EPS of $-0.50. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -30.6%.

The latest indexable market news headline is "CVRx (CVRX) Moves 11.6% Higher: Will This Strength Last?" from Zacks Investment Research.

Additional event context on this page matters because analyst consensus is Buy with a median target of $10.00; recent insider activity includes DALE MICHAEL D filing . These signals are research inputs, not a recommendation.

Valuation

P/E (TTM)

PEG

P/B

4.48

P/S

2.22

EV/EBITDA

-2.58

DCF Value

$-194.11

FCF Yield

-30.6%

Div Yield

0.0%

Margins & Returns

Gross Margin

85.5%

Operating Margin

-84.6%

Net Margin

-89.1%

ROE

-120.8%

ROA

-52.8%

ROIC

-55.2%

Financials

PeriodRevenueNet IncomeEPS
Q1 2026$14.8M$-13.1M$-0.50
Q4 2025$16.0M$-11.9M$-0.46
FY 2025$56.7M$-53.3M$-2.04
Q3 2025$14.7M$-12.9M$-0.49

Analyst Ratings

Consensus

Buy

Target (Consensus)

$10.00

Target (Median)

$10.00

Target Range

$10.00 - $10.00

Strong Buy: 1Buy: 5Hold: 0Sell: 0Strong Sell: 1
Canaccord GenuityBuy
2026-04-14
Canaccord GenuityBuy
2026-02-13
Cantor FitzgeraldOverweight
2025-11-06
Canaccord GenuityBuy
2025-11-06
Cantor FitzgeraldOverweight
2025-08-05

Trading Activity

Insider Trades

DALE MICHAEL D
Sell2026-06-03
DALE MICHAEL Ddirector
Sell2026-06-03
DALE MICHAEL Ddirector
Sell2026-06-03
SHADAN MARTHAdirector
Sell2026-06-03
SHADAN MARTHAdirector
Sell2026-06-03

Company Info

Sector

Healthcare

Industry

Medical - Devices

Country

US

Exchange

Beta

0.77

CVRx, Inc. is a commercial-stage medical technology company focused on innovating, producing, and bringing to market neuromodulation solutions designed for individuals battling cardiovascular diseases. Its principal offering, Barostim, is an advanced neuromodulation device specifically indicated to ameliorate symptoms for patients diagnosed with heart failure characterized by reduced ejection fraction, often referred to as systolic heart failure. The company employs a diverse distribution strategy, leveraging its internal sales force, alongside sales agents and independent distributors, to reach markets across the United States, Germany, the wider European continent, and other global territories. Incorporated in 2000, CVRx, Inc. is headquartered in Minneapolis, Minnesota.